Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + Pembrolizumab + Olaparib in ICI-experienced Recurrent/Advanced Gastric and GEJ Cancer (Phase Ib/II, Single-Arm)
KCT0006101Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, pembrolizumab, olaparib in gastric cancer (GC), esophagogastric junction cancer, sponsored by Merck & Co.. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on KCT0006101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006101.